E3 ubiquitin ligases and their therapeutic potential in disease Management DOI
Geet Madhukar, Md Azizul Haque, Shawez Khan

et al.

Biochemical Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 116875 - 116875

Published: March 1, 2025

Language: Английский

Machine learning identification of a novel vasculogenic mimicry-related signature and FOXM1’s role in promoting vasculogenic mimicry in clear cell renal cell carcinoma DOI Creative Commons
Chao Xu,

Sujing Zhang,

Jingwei Lv

et al.

Translational Oncology, Journal Year: 2025, Volume and Issue: 53, P. 102312 - 102312

Published: Feb. 3, 2025

Language: Английский

Citations

0
Therapeutic Strategies after Imatinib Resistance in Gastrointestinal Stromal Tumors DOI Creative Commons

Linghui Xin,

Peng Liu

International Journal of Biology and Life Sciences, Journal Year: 2025, Volume and Issue: 9(2), P. 20 - 27

Published: Feb. 26, 2025

Gastrointestinal stromal tumor (GIST) is a mesenchymal commonly found in the gastrointestinal tract and its pathogenesis mainly associated with c-KIT PDGFRA gene mutations. Surgery standard treatment for limited GIST, while imatinib (IM) first-line patients advanced or unresectable GIST. However, resistance (both primary secondary resistance) remains major challenge of To address this challenge, second-line drug sunitinib, third-line regorafenib, fourth-line Ripretinib, as well avapritinib targeting D842V mutation, have been introduced into clinic. In addition, therapeutic agents wild-type such SDH-deficient, NTRK-fusion BRAF V600E mutant, shown initial efficacy. Next-generation TKIs other strategies (e.g., heat shock protein inhibitors, mTOR immunotherapy) are still being explored, bringing new hope to drug-resistant future, in-depth study mechanisms, development personalized regimens, exploration combination therapies will hopefully further improve survival quality life GIST patients.

Language: Английский

Citations

0
Role of the circRNA/miRNA/mRNA axis in Renal Cell Carcinoma: from gene regulation to metabolism and immunity DOI Creative Commons

Zhengjun Xu,

Yurong Dong,

Kun Cui

et al.

iScience, Journal Year: 2025, Volume and Issue: 28(4), P. 112183 - 112183

Published: March 12, 2025

Renal cell carcinoma (RCC), particularly clear RCC (ccRCC), has seen rising incidence and mortality rates. Early detection remains difficult due to nonspecific symptoms, often leading diagnoses at advanced stages unfavorable prognoses. Current treatments, including surgery, targeted therapies, immunotherapies, face limitations such as adverse reactions, drug resistance, immune evasion. This review discusses the role of circular RNAs (circRNAs) their involvement in circRNA/miRNA/mRNA axis during progression. As competitive endogenous (ceRNAs), circRNAs regulate gene expression cellular processes, proliferation, metastasis, apoptosis, resistance. Furthermore, we explore impact on tumor metabolic reprogramming influence microenvironment. We also summarize clinical prospects, challenges, future directions this field. A comprehensive understanding these complex interactions may provide new insights into diagnosis treatment RCC, ultimately overcoming existing challenges improving patient outcomes.

Language: Английский

Citations

0
Protein succinylation mechanisms and potential targeted therapies in urinary disease DOI

Y.C. Lou,

Caitao Dong,

Qinhong Jiang

et al.

Cellular Signalling, Journal Year: 2025, Volume and Issue: unknown, P. 111744 - 111744

Published: March 1, 2025

Language: Английский

Citations

0
E3 ubiquitin ligases and their therapeutic potential in disease Management DOI
Geet Madhukar, Md Azizul Haque, Shawez Khan

et al.

Biochemical Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 116875 - 116875

Published: March 1, 2025

Language: Английский

Citations

0